The aim of the study was to evaluate the efficacy of orally administered bovine lactoferrin (bLF) on Urinary Tract Infections in neonates and infants. Fifty-five patients with urinary tract infection were randomized to receive either bLF (n = 27) or an identical placebo (n = 28) for 4 weeks. The patients were assessed clinically and laboratory.
Age range
7 Days – 12 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Monitoring of parameters of inflammation.
Timeframe: at baseline, after 5 days of treatment
Influence of lactoferrin on Interleukin-6 and Interleukin-8.
Timeframe: at baseline, after 5 days of treatment
Effect of lactoferrin on white blood cells.
Timeframe: at baseline, after 5 days of treatment
Effect of lactoferrin on urinary inflammatory markers.
Timeframe: at baseline, after 5 days of treatment